The Latest Cardiac and Vascular News
Clearance brings full cerebral and systemic embolic protection to patients undergoing transcatheter aortic valve replacement (TAVR) SANTA CRUZ, Calif., Sept. 9, 2026 /PRNewswire/ — Emboline, Inc., a medical technology company developing next-generation embolic protection technology,…
The upgrade accelerates a health system’s capability to go from reactive to proactive cardiovascular care along guideline-directed treatment pathways ALISO VIEJO, Calif., Sept. 8, 2026 /PRNewswire/ — egnite, Inc., a healthcare AI company focused on helping clinicians identify and manage…
PHocus met its primary endpoint, demonstrating a clinically meaningful and statistically significant placebo-adjusted reduction in pulmonary vascular resistance (PVR) of -56.3% (p
First comprehensive systematic review provides insights into the long-term safety profile of angiogenic approaches in coronary artery disease Data shows no evidence of increased cancer or retinopathy, resolving long-standing safety questions that have limited progress across the field…
CARLSBAD, Calif.–(BUSINESS WIRE)–Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner Novartis today announced that the pelacarsen Phase 3 Lp(a)HORIZON study, a pioneering cardiovascular outcomes trial, did not meet its primary endpoint of reducing the risk of cardiovascular events, a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and urgent coronary revascularization requiring hospitalization, compared to placebo. Consistent with previous studies, substan
NEWTON, Mass. and MILAN, Sept. 3, 2026 /PRNewswire/ — InnovHeart, a medical device company developing the Saturn Transseptal Transcatheter Mitral Valve Replacement (TMVR) System, today announces the successful implantation of the first U.S. patient with the Saturn system as part of the…
DENVER–(BUSINESS WIRE)– #AI–Cleerly, a leader in advanced cardiovascular imaging analysis, today announced findings from a study of 1,385 patients with suspected coronary artery disease (CAD) presented at the European Society of Cardiology (ESC) Congress 2026 in Munich. The study, titled “Temporal associations of coronary plaque burden and myocardial perfusion with clinical outcomes,” was led by Jorge Dahdal, MD, of Clínica Alemana de Santiago, Chile, and Amsterdam UMC, the Netherlands, and presen
GALWAY, Ireland and REHOVOT, Israel, Sept. 1, 2026 /PRNewswire/ — Medtronic plc (NYSE: MDT), a global leader in healthcare technology, and Pi-Cardia Ltd., a pioneer in leaflet modification technologies for structural heart disease, today announced a strategic investment by Medtronic in…
New single-arm, open-label data extend the body of evidence supporting consistent clinical benefit and safety with Camzyos, adding to the longest-running clinical development experience for a cardiac myosin inhibitor (CMI) in symptomatic oHCM Additional presentations at ESC Congress build upon the established effectiveness and safety profile of Camzyos in real-world settings PRINCETON, N.J.–(BUSINESS […]
AMSTERDAM & MEXICO CITY–(BUSINESS WIRE)–Lapsi Health, the clinical AI company behind the Keikku AI Clinical Platform, and the Sociedad Mexicana de Cardiología (SMC) today announced a strategic clinical, scientific and educational collaboration designed to make trusted cardiovascular guidance more accessible to healthcare professionals in Mexico. Through the collaboration, mutually identified clinical guidelines, consensus statements, clinical recommendations, scientific guidance and other edu
